Example: Heart Attack

Search clinical trials for: Anastrozole

Total 339 results

NCT04460911

Active, not recruiting

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Conditions: Breast Cancer
NCT04445922

Not yet recruiting

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition

Conditions: Healthy Volunteers
NCT04438733

Recruiting

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted Condition

Conditions: Healthy Volunteers
NCT04436744

Not yet recruiting

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer

Conditions: Early Breast Cancer
NCT04389424

Recruiting

Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer

Conditions: Breast Cancer; Endocrine Therapy; Endocrine Therapy Adverse Reaction; Vitamin D Deficiency; Nutrition Disorders; Obesity
NCT04383275

Not yet recruiting

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Conditions: Breast Cancer
NCT04352777

Not yet recruiting

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Conditions: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor
NCT04316169

Not yet recruiting

Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors

Conditions: Solid Tumor; Advanced Breast Cancer
NCT04294225

Recruiting

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
NCT04272801

Recruiting

Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer

Conditions: Breast Cancer Female
NCT04258163

Completed

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Conditions: Metastatic Breast Cancer
NCT04256941

Recruiting

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
NCT04236310

Not yet recruiting

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Conditions: Breast Cancer; HER2-positive Breast Cancer; ER-positive Breast Cancer
NCT04227327

Recruiting

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Conditions: Advanced Breast Cancer
NCT04158362

Recruiting

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Conditions: Cancer Metastatic
NCT04134598

Not yet recruiting

ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years With Luminal-A Early Stage Breast Cancer (EUROPA)

Conditions: Breast Cancer
NCT04113863

Recruiting

ATRA Trial - ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER eBC ATRA TRIAL

Conditions: Breast Neoplasm Female
NCT04088032

Not yet recruiting

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Conditions: Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast
NCT04088110

Not yet recruiting

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Conditions: Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor
NCT04075604

Recruiting

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Conditions: Breast Cancer; Cancer
NCT04023292

Recruiting

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Conditions: Breast Neoplasms
NCT04012918

Recruiting

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

Conditions: Metastatic Breast Cancer
NCT03988114

Withdrawn

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Conditions: Metastatic Breast Cancer
NCT03966898

Recruiting

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Conditions: Advanced Breast Cancer
NCT03948568

Recruiting

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

Conditions: Early-stage Breast Cancer
NCT03944434

Recruiting

FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer

Conditions: Breast Cancer
NCT03933618

Completed

Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

Conditions: Hypogonadism, Male
NCT03925233

Enrolling by invitation

Breast Cancer Treatment Based on Organ-like Culture

Conditions: Breast Cancer Organoids
NCT03910712

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Conditions: Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor
NCT03874325

Recruiting

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Conditions: Breast Cancer; Hormone Receptor Positive Tumor
NCT03839823

Recruiting

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT03822468

Recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Conditions: Breast Cancer
NCT03820830

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Conditions: Breast Cancer Recurrent
NCT03778931

Recruiting

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Conditions: Breast Cancer
NCT03768258

Completed

Testosterone Implants and the Incidence of Breast Cancer

Conditions: Breast Cancer
NCT03691493

Recruiting

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8
NCT03671330

Active, not recruiting

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Conditions: Breast Cancer
NCT03624244

Recruiting

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Conditions: Low Grade Endometrial Stromal Sarcoma
NCT03555877

Unknown status

Anti-hormonal Therapie With or Without Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Conditions: Breast Cancer Metastatic
NCT03554044

Recruiting

Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer

Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma
NCT03541863

Completed

Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

Conditions: Breast Cancer
NCT03490513

Recruiting

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

Conditions: Hypogonadism, Hypogonadotropic; Obesity
NCT03481998

Recruiting

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Conditions: Advanced Breast Cancer
NCT03425838

Recruiting

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Conditions: Breast Neoplasm Female
NCT03421639

Unknown status

Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids

Conditions: Uterine Fibroid; Uterine Bleeding
NCT03324932

Recruiting

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Conditions: Breast Cancer
NCT03321981

Active, not recruiting

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer

Conditions: Breast Cancer Metastatic
NCT03314298

Completed

A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole

Conditions: Mammographic Density
NCT03312738

Active, not recruiting

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Conditions: Advanced Breast Cancer
NCT03304080

Recruiting

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast

Conditions: Breast Neoplasms; Breast Diseases